Drugs

Adding an SGLT-2 Inhibitor Can Mean Less Insulin Needed

For patients with type 2 diabetes who need large doses of insulin, adding an SGLT2 inhibitor to insulin therapy can mean much less insulin is needed according to new research. Patients with daily insulin doses between 101 and 200 units experienced an insulin dose reduction of 17 units/day with the addition of canagliflozin (brand name […]

SGLT-2 Inhibitors: What you Need to Know to Prevent Kidney Problems

SGLT-2 inhibitor drugs (brand names include Invokana and Jardience) have many benefits, but have been associated with diabetes ketoacidosis (DKA), a serious kidney problem, in people with type 2. If you are taking an SGLT-2 inhibitor, it’s important to know the signs of DKA and how to protect yourself. Read more

New Discovery May Make Diabetes Drugs Easier to Tolerate

Side effects of diabetes drugs like nausea and vomiting make them difficult to tolerate for many people, and may even cause some to stop taking their medications or take them at reduced levels. New research has found that modifying a key ingredient in GLP-1 type diabetes drugs produces a compound that was effective for hyperglycemia […]

Using an SGLT-2 Inhibitor Drug Has Benefits for Type 1

New research suggests that adding an SGLT-2 inhibitor drug, dapagliflozin, to insulin therapy is helpful to patients with type 1 diabetes who are not able to maintain ideal blood glucose ranges with insulin alone. Because the drug can cause a slight increase in the kidney problem DKA, patients and their doctors should work closely together […]

SGLT-2 / GLP-1 Drug Combo Shows Multiple Benefits for Diabetes

When combined, SGLT2 Inhibitor and GLP-1 RAs drugs show multiple benefits in treatment of type 2 diabetes. According to studies, the drug combination can target most of the issues that contribute to glucose intolerance, aiding in blood sugar control, weight management, blood pressure reduction, among others. Read more

New SGLT-2 Inhibitor May be Helpful for Type 1 Diabetes

Sotagliflozin (brand name Zynquista), will be reviewed by the FDA as a possible adjunct treatment, along with insulin, for type 1 diabetes. If approved, it will be the first oral antidiabetes medication used in combination with insulin in patients diagnosed with type 1 diabetes.  Read more

Can Diabetes Drugs Fight Alzheimer’s?

Many recent clinical trials of new drugs for Alzheimer’s disease have ending in failure, and now some scientists are reconsidering whether we’ve been looking at the wrong things in our attempts to understand and treat the disease. Some researchers are now looking at the relationship between diabetes and Alzheimer’s, and how insulin may be the […]

“Surgery in a Pill” May Mimic Benefits of Bariatric Surgery

Researchers have conducted a study to examine whether it is possible to create a less invasive alternative to bariatric surgery that would be equally effective in reversing type 2 diabetes, and offer the same benefits as surgery. The treatment would be in the form of an oral agent that would temporarily coat the intestine to […]

What You Need to Know about the Trump Drug Pricing Reform Plan

Whatever your political views, it’s important to understand the implications of the new information issued by the Department of Health and Human Services (HHS) describing how the Trump administration plans to drop the prices for prescription drugs for all Americans. The first part of this plan will be implemented right away, while the second part […]

Four Exciting New Diabetes Drugs in Development

Four new drugs now in development could change the way diabetes is treated. Novo Nordisk’s oral GLP-1 Semaglutide could offer an easier-to-take option and help delay the need for direct insulin treatment. Opko’s Oxyntomodulin (OPK-88003) is a leader in a new class of dual GLP-1 and glucagon receptor agonist drugs. Oramed just started a Phase 2 […]

What Your Doctor Needs to Know about Prescribing SGLT-2s

In the last two years, the FDA has approved four drugs in the SGLT-2 inhibitors class: canagliflozin (brand name Invokana, Jansssen), dapagliflozin (brand name Farxiga, AstraZeneca), empagliflozin (brand name Jardiance, Boehringer Ingelheim), and ertugliflozin (brand name Steglatro, Merck/Pfizer). What is important for doctors to know about these new drugs, and how they should be prescribed? […]

Things to Consider When Changing from Daily to Weekly GLP-1

Changing from a once-a-day dose to a once-a-week dose of a GLP-1 medication can sometimes be confusing. It’s important to get the timing right when you stop the daily dose and start the weekly dose. And it doesn’t help that the pens for a daily medication like Victoza look very similar to the pens for […]

Doctors and Patients Protest Insulin Costs

Diabetes activists, including both physicians and patients, joined together in Washington, DC this past weekend to protest the high cost of insulin in the U.S. The protest was held on April 8 and organized by  the Right Care Alliance, an activist group that states their mission is to hold “health care institutions accountable to communities […]

SGLT-2 Inhibitors for Patients with Obesity

Many patients with diabetes struggle with weight management, and many drugs used to treat diabetes can further contribute to weight gain. Researchers have found that the SGLT-2 inhibitors, a newer class of drugs, are very effective when combined with diet and exercise in helping patients lose weight. Researchers have found that the amount of weight […]

Major Analysis Looks at Long-Term Safety of SGLT-2 Drugs

SGLT-2 inhibitors are the newest diabetes drug class on the market, and to date research on their long-term safety has been lacking. The American Heart Association has published the results of a major meta analysis which reviewed all the available trials and studies. The researchers found that use of SGLT-2 inhibitors led to a 20% […]

Will New Once-Daily Pill Replace Insulin Injections?

Novo Nordisk, the world’s largest insulin manufacturer, is looking to transform the diabetes market with a pill. Its oral semaglutide medicine is currently in late-stage trials, with a planned launch date in 2020. Semaglutide, one of the GLP-1 drugs, stimulates insulin production. It’s currently available as a once-weekly injection, and Novo hopes that the pill […]

Reducing Heart Disease Risk with Diabetes

People with diabetes are more than twice as likely to die from heart disease as those without diabetes. To help reduce the risk of heart disease and manage type 2 diabetes, it’s important to eat healthy diet rich in vegetables, fruits, whole grains, lean protein, and healthy fats, along with getting regular exercise. But even […]

New Japanese Drug May Help Lipid Profiles

A new drug, Pemafibrate, currently in a phase 3 clinical trial in Japan, may significantly improve lipid profiles and insulin resistance in patients with type 2 diabetes and hypertriglyceridemia. The results follow those of several large-scale clinical trials which show that treatment with drugs of the fibrate class can decrease triglyceride levels and increase high-density […]

Can Software Help Make Diabetes Care More Individualized and Affordable?

Every day, doctors and other prescribers write prescriptions for patients with diabetes. But how can they choose the best medication from all the many drugs, and combination drugs, available today? And how can they make sure that the patient will be able to afford the drug they want to prescribe, when there are more than […]

Drugs Play a Role in Weight Management with Diabetes

Obesity and diabetes are often linked, and prescription drugs can have varying effects on weight. Research has found that certain drug types such as sodium-glucose cotransporter 2 (SGLT-2) inhibitors (for example, Invokana and Jardiance) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (for example, Victoza and Trulicity) may help with weight loss. On the other hand, […]